- Home
- OCS vs CLVT Comparison
OCS vs CLVT Comparison
Compare OCS & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCS | CLVT |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | 12000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OCS | CLVT |
|---|---|---|
| Price | $25.31 | $2.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | ★ $41.86 | $3.22 |
| AVG Volume (30 Days) | 366.1K | ★ 7.1M |
| Earning Date | 03-03-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $418.43 | N/A |
| Revenue Next Year | $892.34 | $2.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.00 | $1.66 |
| 52 Week High | $30.68 | $4.77 |
Technical Indicators
Market Signals| Indicator | OCS | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 53.19 |
| Support Level | $19.00 | $1.66 |
| Resistance Level | $29.19 | $2.75 |
| Average True Range (ATR) | 1.32 | 0.17 |
| MACD | -0.37 | 0.02 |
| Stochastic Oscillator | 7.99 | 58.88 |
Price Performance
Historical ComparisonAbout OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.